1 Needs context
The recommended dietary intake target for choline is approximately 550 mg per day for adults.
"so I'm getting around 550 mg per day, which is the the goal for most of us." (said at 1:05:38)
Dietary guidelines set by the Institute of Medicine (now the National Academy of Medicine) established an Adequate Intake (AI) for choline of 550 mg/day specifically for adult men (as well as lactating females). For non-pregnant adult women, the AI is 425 mg/day (increasing to 450 mg/day in pregnancy). Therefore, 550 mg/day is the target for adult men rather than all adults in general.
- context: Choline: are our university students eating enough? (The West Indian medical journal 2006) · cited 9x in the literature
"The analysis revealed that 86.2% of the females and 90.9% of the males reported diets that delivered less daily choline than the adequate intake quoted by the Institute of Medicine of the National Academy of Sciences, USA (425-550 mg/day)." (abstract, results, passage verified)
pubmedfull study (doi) - context: Sex and menopausal status influence human dietary requirements for the nutrient choline. (The American journal of clinical nutrition 2007) · cited 350x in the literature
"Moreover, 6 men developed these signs while consuming 550 mg choline x 70 kg(-1) x d(-1), the AI for choline." (abstract, results, passage verified)
pubmedfull study (doi) - context: Pre- and postnatal health: evidence of increased choline needs. (Journal of the American Dietetic Association 2010) · cited 159x in the literature
"Although human beings' requirement for choline is unknown, an Adequate Intake level of 425 mg/day was established for women with upward adjustments to 450 and 550 mg/day during pregnancy and lactation, respectively." (abstract, background, passage verified)
pubmedfull study (doi)
28 Supported by research
A 9-month proof-of-concept trial of the Bredesen protocol showed that approximately 80% of patients improved in cognitive measures including MoCA, CNS Vital Signs, and AQ-C scores, and had better MRI volume outcomes than typical decline.
"Dr. Bredesen has a new study out that we are going to review, a 9-month study that had an 80% improvement, rather 80% of the individuals in his program undergoing his treatment protocol improved" (said at 0:01:35)
A 9-month proof-of-concept trial of a multi-modal precision medicine protocol (the Bredesen protocol) in 25 patients with mild cognitive impairment or early dementia evaluated outcomes using MoCA, CNS Vital Signs Neurocognitive Index, the Alzheimer's Questionnaire Change score (AQ-C), and brain MRI volumetrics. The published pilot study reported statistically significant improvements across all of these cognitive measures and MRI volumetric parameters over the 9-month intervention. However, because this was a small, open-label pilot study without a randomized, parallel control group, the certainty of evidence for clinical efficacy is very low due to potential risks of practice effects, placebo effects, and regression to the mean.
Eli Lilly's monoclonal antibody donanemab was shown to slow the decline of Alzheimer's disease by 32%.
"Eli Lilly's new monoclonal antibody, donanemab, that it was so great that the stock of Eli Lilly went up billions of dollars with an announcement that it actually slowed the decline of Alzheimer's by a third, 32%." (said at 0:08:50)
In the double-blind, randomized Phase 2 TRAILBLAZER-ALZ clinical trial funded by Eli Lilly and published in the New England Journal of Medicine, donanemab slowed cognitive and functional decline in early symptomatic Alzheimer's disease by approximately 32% at 76 weeks on the primary composite outcome, the Integrated Alzheimer's Disease Rating Scale (iADRS). The change from baseline was -6.86 in the donanemab group compared to -10.06 in the placebo group (difference: 3.20 points, P = 0.04), representing a 31.8% (rounded to 32%) reduction in decline.
Research by Rudolph Tanzi and Robert Moir demonstrated that beta-amyloid is an antimicrobial peptide with antiviral and antifungal properties.
"our colleague Rudy Tanzi, along with the late Robert Moir, showed a number of years ago that amyloid is actually quite a good antimicrobial peptide. Interestingly, it has antiviral properties and antifungal properties." (said at 0:18:30)
Preclinical studies led by Robert Moir and Rudolph Tanzi demonstrated that amyloid-beta (Aβ) functions as an antimicrobial peptide in the innate immune system. In 2010 and 2016, they showed in vitro and in animal models (mice and nematodes) that Aβ inhibits clinically relevant pathogens, protecting against bacterial and fungal infections (such as Candida albicans). In 2018, they demonstrated antiviral properties, showing that Aβ oligomers bind herpesvirus surface glycoproteins (HSV-1 and HHV-6) and entrap viral particles in cell culture and transgenic mouse models. Because these findings are derived from cell cultures and animal models, the certainty of evidence is very low.
- supports: The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. (PloS one 2010) · cited 1041x in the literature
"Here, we provide data supporting an in vivo function for Abeta as an antimicrobial peptide (AMP). Experiments used established in vitro assays to compare antimicrobial activities of Abeta and LL-37, an archetypical human AMP. Findings reveal that Abeta exerts antimicrobial activity against eight common and clinically relevant microorganisms with a potency equivalent to, and in some cases greater than, LL-37." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheim… (Science translational medicine 2016) · cited 985x in the literature
"We present in vivo data showing that Aβ expression protects against fungal and bacterial infections in mouse, nematode, and cell culture models of AD. We show that Aβ oligomerization, a behavior traditionally viewed as intrinsically pathological, may be necessary for the antimicrobial activities of the peptide." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect aga… (Neuron 2018) · cited 690x in the literature
"Here, we show Aβ oligomers bind herpesvirus surface glycoproteins, accelerating β-amyloid deposition and leading to protective viral entrapment activity in 5XFAD mouse and 3D human neural cell culture infection models against neurotropic herpes simplex virus 1 (HSV1) and human herpesvirus 6A and B." (abstract, results, passage verified)
pubmedfull study (doi)
In the donanemab trial, the treatment group showed measurable brain tissue loss (atrophy) compared to the placebo group.
"First, the donanemab study, interestingly, in the treated group demonstrated measurable loss of tissue, atrophy, if you will, in comparison to the placebo group." (said at 0:22:06)
Randomized clinical trials evaluating anti-amyloid monoclonal antibodies, including donanemab (e.g., TRAILBLAZER-ALZ trials), demonstrated that participants in the active treatment group experienced accelerated brain volume loss (greater decreases in whole brain and cortical volume, along with greater ventricular enlargement) on MRI compared to the placebo group. While the precise biological mechanisms behind this phenomenon continue to be studied (e.g., clearance of amyloid plaques, reduction in inflammation-associated edema, or pseudoatrophy vs. neurotoxicity), the finding of measurable excess brain volume reduction in the treated arm relative to placebo is well-documented.
Research by Ruth Itzhaki demonstrated colocalization of beta-amyloid with herpes simplex virus.
"And even prior to Rudolph Tanzi, Ruth Itzhaki in England showed colocalization of beta amyloid to herpes simplex, indicating exactly what you said, that the amyloid is a response element." (said at 0:22:40)
Ruth Itzhaki and colleagues published a 2009 study using in situ polymerase chain reaction (PCR) combined with immunohistochemistry or thioflavin S staining in post-mortem human brain sections, demonstrating that herpes simplex virus type 1 (HSV-1) DNA was specifically localized within amyloid-beta plaques (found in 90% of plaques in Alzheimer's disease brains). The authors concluded this direct association suggests HSV-1 infection leads to amyloid accumulation as a response.
Research by Stuart Lipton showed that anti-amyloid antibodies trigger an inflammatory response in the brain.
"And Stuart found that when you look at the brains when you give these antibodies, it actually causes inflammation." (said at 0:23:40)
Research from Stuart Lipton's laboratory (Trudler et al., PNAS 2021) demonstrated that complexes of antibodies with misfolded target proteins (including amyloid-β and α-synuclein) paradoxically activated the NLRP3 inflammasome and exacerbated interleukin-1β secretion and neuroinflammation in human iPSC-derived microglia and in humanized mouse brains. Because the findings derive from cell culture and animal models rather than direct human clinical trials, the GRADE certainty is very low.
Insulin-degrading enzyme (IDE) degrades both insulin and beta-amyloid.
"We can upregulate insulin-degrading enzyme by becoming more insulin sensitive through dietary means. And as such, you know, recognize that this enzyme that degrades insulin is also involved in the degradation of beta amyloid." (said at 0:26:11)
The host's statement that insulin-degrading enzyme (IDE) degrades both insulin and beta-amyloid, and that IDE expression and activity can be upregulated through dietary interventions improving insulin sensitivity, is fully supported by published literature. IDE (a zinc metalloendopeptidase) is well established as a primary enzyme responsible for the proteolytic degradation and extracellular clearance of both insulin and amyloid-beta (Aβ) peptides. Furthermore, animal studies demonstrate that high-fat diet-induced insulin resistance decreases IDE expression and function, whereas dietary interventions that improve insulin sensitivity (such as caloric restriction, dietary polyphenols/curcumin, or reversing high-fat diet effects) restore or upregulate hepatic and renal IDE expression and clearance activity.
- supports: Dietary curcumin enhances insulin clearance in diet-induced obese mice via regulation of h… (Nutrition & metabolism 2019) · cited 38x in the literature
"Mice given HFS + CUR had reduced body weight and fat accumulation in the liver and had lower blood insulin levels under fasting conditions compared to mice on HFS alone, resulting from significantly improved insulin clearance via upregulation of hepatic insulin-degrading enzyme (IDE)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications o… (Pharmaceutical research 2022) · cited 22x in the literature
"The IDE is a large zinc-metalloprotease that breakdown numerous pathophysiologically important extracellular substrates, comprising amyloid β-protein (Aβ) and insulin." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Long-Term High-Fat Diet Decreases Renal Insulin-Degrading Enzyme Expression and Function b… (Molecular nutrition & food research 2023) · cited 8x in the literature
"Long-term HFD decreases renal IDE expression and activity, and causes insulin resistance, which involves PPARγ." (abstract, conclusion, passage verified)
pubmedfull study (doi) - supports: Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degrada… (The Journal of biological chemistry 1998) · cited 802x in the literature
"The major such protease identified was a metalloprotease released particularly by a microglial cell line, BV-2. We have now purified and characterized the protease and find that it is indistinguishable from insulin-degrading enzyme (IDE), a thiol metalloendopeptidase that degrades small peptides such as insulin, glucagon, and atrial natriuretic peptide." (abstract, results, passage verified)
pubmedfull study (doi)
Approximately 80 million Americans have insulin resistance or are on their way to type 2 diabetes.
"HOST: That's 80 million Americans.
GUEST1: Exactly." (said at 0:27:45)
According to national surveillance data from the Centers for Disease Control and Prevention (CDC) and the National Health and Nutrition Examination Survey (NHANES), an estimated 84 million to 98 million American adults have prediabetes—an intermediate state of progressive dysglycemia characterized by insulin resistance and impaired glucose regulation that precedes type 2 diabetes. The statement that approximately 80 million Americans have insulin resistance or are on their way to type 2 diabetes accurately reflects these national epidemiological figures.
Bioenergetic defects in the brain during Alzheimer's disease pathogenesis can predate the onset of clinical cognitive symptoms by 20 to 30 years.
"So, why don't we start with the notion that there is a bioenergetic defect in the Alzheimer's brain that may predate the onset of clinical symptoms by 20, even perhaps 30 years." (said at 0:11:52)
The host's statement accurately reflects the established scientific understanding of Alzheimer's disease (AD) pathophysiology. Multiple neuroimaging (such as FDG-PET) and bioenergetic studies have demonstrated that reductions in cerebral glucose metabolism, mitochondrial dysfunction, and declining ATP production can be detected during the preclinical phase, often 20 to 30 years (or decades) before the onset of overt clinical dementia and cognitive symptoms, particularly in populations at elevated risk (such as APOE ε4 carriers or perimenopausal/postmenopausal cohorts).
Type 2 diabetes is associated with an increased risk of developing Alzheimer's disease.
"You know, we've known for years that there's an increased risk of Alzheimer's in type 2 diabetics, hence the call to get your blood sugar under control" (said at 0:16:58)
Large-scale prospective cohort studies and meta-analyses consistently demonstrate that individuals with diabetes mellitus (predominantly type 2 diabetes) have a significantly higher risk of developing Alzheimer's disease compared to individuals without diabetes. A meta-analysis of 17 longitudinal population-based cohort studies comprising over 1.7 million individuals found that diabetes was associated with an approximately 53% increased risk of Alzheimer's disease (RR 1.53, 95% CI 1.42–1.63). Additionally, poor glycaemic control, longer diabetes duration, and episodes of hypoglycaemia in individuals with type 2 diabetes are prospectively associated with increased risks of dementia and Alzheimer's disease.
- supports: An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer's disease. (Diabetes research and clinical practice 2017) · cited 389x in the literature
"A total of 17 studies involving 1,746,777 individuals were included. After pooling these 17 studies, subjects with diabetes had significant higher incidence of AD than those without diabetes (RR: 1.53, 95% CI: 1.42-1.63)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Associations of glycaemia-related risk factors with dementia and cognitive decline in indi… (Diabetic medicine : a journal of the British Diabetic Association 2025) · cited 15x in the literature
"Having a history of hypoglycaemia, longer diabetes duration, and higher HbA1c levels and variability were related to higher dementia risk in people with type 2 diabetes." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Beta-amyloid triggers both the pathological phosphorylation of tau protein and the production of reactive oxygen species in the brain.
"you're going to continue to make the beta amyloid that is part of that innate system, and it is going to trigger the phosphorylation of tau, and trigger the reactive oxygen species you referred to, and trigger the downsizing of your brain" (said at 0:25:10)
Extensive preclinical and mechanistic research demonstrates that amyloid-beta (Aβ) exposure triggers both the hyperphosphorylation of tau protein and the generation of reactive oxygen species (ROS) / oxidative stress in neuronal and glial models. Human neuronal and cellular assays show that exposure to Aβ oligomers induces marked increases in ROS production, mitochondrial dysfunction, and pathological tau phosphorylation at Alzheimer's disease-associated epitopes. Because this evidence is derived from in vitro, ex vivo, and animal mechanistic models rather than clinical trial endpoints, the GRADE certainty is rated very low.
- supports: Molecular Mechanisms of Alzheimer's Disease Induced by Amyloid-β and Tau Phosphorylation A… (Cells 2025) · cited 27x in the literature
"Tau protein has also been identified as a significant factor in AD. In particular, Tau phosphorylation is crucial for neuronal impairment, as phosphorylated Tau detaches from microtubules, leading to the formation of neurofibrillary tangles and the destabilization of the microtubule structure. This instability in microtubules damages axons and dendrites, resulting in neuronal impairment. Notably, Aβ is linked to Tau phosphorylation." (abstract, passage verified)
pubmedfull study (doi) - supports: A Proteomics Profiling Reveals the Neuroprotective Effects of Melatonin on Exogenous β-amy… (Cell biology international 2025) · cited 9x in the literature
"Our results show that Aβ42 exposure led to an increase in an accumulation of intracellular Aβ42/40 and phosphorylated tau (Thr181)/Tau ratios." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Extracellular vesicles from hiPSC-derived NSCs protect human neurons against Aβ-42 oligome… (Stem cell research & therapy 2025) · cited 14x in the literature
"A significant neurodegeneration was observed when human neurons were exposed to Aβ-42o alone. Neurodegeneration was associated with (1) elevated levels of reactive oxygen species (ROS), mitochondrial superoxide, malondialdehyde (MDA) and protein carbonyls (PCs), (2) increased expression of proapoptotic Bax and Bad genes and proteins, and genes encoding mitochondrial complex proteins, (3) diminished mitochondrial membrane potential and mitochondria, (4) reduced expression of the antiapoptotic gene and protein Bcl-2, and autophagy-related proteins, and (5) increased phosphorylation of tau." (abstract, results, passage verified)
pubmedfull study (doi)
Elevated fasting blood glucose levels and elevated cortisol levels are associated with hippocampal volume reduction.
"As your glucose goes up, your hippocampus shrinks down. Same for cortisol. Cortisol up, hippocampus down." (said at 0:30:37)
Human observational neuroimaging studies support the association between higher fasting blood glucose levels and reduced hippocampal volume, even within non-diabetic or subclinical glucose ranges. Similarly, studies measuring systemic cortisol levels (in healthy older adults, Alzheimer's disease patients, and individuals with hypercortisolism/Cushing's disease) demonstrate significant negative correlations between serum cortisol levels and hippocampal volume.
- supports: Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Stud… (Neurology 2012) · cited 168x in the literature
"High plasma glucose levels within the normal range (<6.1 mmol/L) were associated with greater atrophy of structures relevant to aging and neurodegenerative processes, the hippocampus and amygdala." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Higher glucose levels associated with lower memory and reduced hippocampal microstructure. (Neurology 2013) · cited 210x in the literature
"Lower HbA1c and glucose levels were significantly associated with better scores in delayed recall, learning ability, and memory consolidation." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Serum cortisol is negatively related to hippocampal volume, brain structure, and memory pe… (Frontiers in aging neuroscience 2023) · cited 48x in the literature
"Furthermore, higher cortisol levels were significantly associated with smaller left hippocampal volumes in HS and indirectly negatively correlated to memory function through hippocampal volume." (abstract, results, passage verified)
pubmedfull study (doi)
Neuropathological evaluations of COVID-19 patient brains show microthrombosis, microhemorrhage, inflammatory cells, and megakaryocytes.
"And when you actually look at the brains as you indicated, you see microthrombosis, you see microhemorrhage, you see inflammatory cells. There was even a report of megakaryocytes as it being a question of one issue." (said at 0:36:26)
Postmortem and neuropathological examinations of patients who died with COVID-19 document vascular injury and neuroinflammatory changes, including cerebral infarction, microvascular thrombosis, intracranial hemorrhage/microhemorrhages, and neuroinflammation. In addition, autopsy studies have specifically identified the atypical presence of intracapillary megakaryocytes within the cerebral vasculature of COVID-19 patients.
- supports: Postmortem Findings Associated With SARS-CoV-2: Systematic Review and Meta-analysis. (The American journal of surgical pathology 2021) · cited 101x in the literature
"Remarkable postmortem findings in association with COVID-19 apart from DAD include pulmonary hemorrhage, viral cytopathic effect within pneumocytes, thromboembolism, brain infarction, endotheliitis, acute renal tubular damage, white pulp depletion of the spleen, cardiac myocyte necrosis, megakaryocyte recruitment, and hemophagocytosis." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Neuropathological findings in COVID-19 vs. non-COVID-19 acute respiratory distress syndrom… (Frontiers in neurology 2023) · cited 2x in the literature
"The frequency of overall ABI (70 vs. 60%), infratentorial ABI (40 vs. 25%), ischemic infarct (40 vs. 25%), intracranial hemorrhage (30 vs. 35%), and hypoxic-ischemic brain injury (30 vs. 35%) was similar between COVID-19 and non-COVID-19 ARDS patients, respectively ( p > 0.05). Intracapillary megakaryocytes were exclusively seen in 30% of COVID-19 patients." (abstract, results, passage verified)
pubmedfull study (doi)
Postmortem brain examinations of individuals exposed to MPTP in 1983 revealed persistent, ongoing microglial activation years after the initial exposure.
"I remember research that looked at the MPTP individuals in 1983 in Southern—was it Southern California or San Francisco?—who experimented with a synthetic Demerol and ultimately immediately by virtue of the damage to the mitochondria in the part of the brain that creates the dopamine that is involved in the motor system, these individuals developed Parkinson's. But, what's interesting, the reason I'm bringing it up, not that that's uninteresting, is that when these individuals years later passed away, there was still ongoing microglial activation." (said at 0:38:29)
A landmark 1999 postmortem neuropathological study by Langston and colleagues examined three individuals who developed severe parkinsonism after exposure to MPTP (a contaminant in synthetic opioids) in northern California in the early 1980s. Surviving between 3 and 16 years following the initial time-limited exposure, postmortem examination of their substantia nigra revealed persistent gliosis and active clustering of microglia around nerve cells alongside ongoing nerve cell loss. As this evidence comes from a small autopsy case series (n = 3), the certainty of evidence for this specific historical cohort is graded very low.
- supports: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1… (Annals of neurology 1999) · cited 969x in the literature
"Survival times ranged from 3 to 16 years. Neuropathological examination revealed moderate to severe depletion of pigmented nerve cells in the substantia nigra in each case. Lewy bodies were not present. In Patients 1 and 2, there was gliosis and clustering of microglia around nerve cells. Patient 3 had a similar picture and also showed large amounts of extraneuronal melanin. These findings are indicative of active, ongoing nerve cell loss, suggesting that a time-limited insult to the nigrostriatal system can set in motion a self-perpetuating process of neurodegeneration." (abstract, results, passage verified)
pubmedfull study (doi)
In a 2015 study and follow-up evaluation, approximately 12.8% to 14% of World Trade Center first responders presented with cognitive decline.
"And another great example, of course, the World Trade Center first responders were evaluated in 2015, years after the original problem. And it turned out that 12.8% of them—and then actually a follow-up paper a little higher, about 14% of them—actually had cognitive decline." (said at 0:41:10)
The speaker's statement accurately reflects findings from published epidemiological studies evaluating World Trade Center (WTC) first responders. In an evaluation conducted between January 2014 and April 2015 by Clouston et al. (published in 2016 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring), screening of 818 WTC responders using the Montreal Cognitive Assessment (MoCA) revealed that approximately 12.8% had scores indicative of cognitive impairment (and 1.2% had scores indicating possible dementia, totaling ~14%). Subsequent analyses across WTC cohorts have continued to document similar and expanding rates of mild cognitive impairment and cognitive decline.
Cyanobacterial blooms produce the neurotoxin beta-N-methylamino-L-alanine (BMAA).
"we're having these incredible fish kills as a consequence of red tide, incredible overgrowth of cyanobacteria and known to produce BMAA." (said at 0:46:36)
Published environmental toxicology research and chemical analyses confirm that blooms of various cyanobacterial species produce the non-protein amino acid neurotoxin β-N-methylamino-L-alanine (BMAA) along with its structural isomers.
- supports: The Changes in Cyanobacterial Concentration of β-Methylamino-L-Alanine during a Bloom Even… (Molecules (Basel, Switzerland) 2022) · cited 5x in the literature
"β-N-methylamino L-alanine (BMAA) is a neurotoxin linked to high incidences of neurodegenerative disease. The toxin, along with two of its common isomers, 2,4-diaminobuytric acid (2,4-DAB) and N-(2-aminoethyl)glycine (AEG), is produced by multiple genera of cyanobacteria worldwide." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Microbial Diversity Impacts Non-Protein Amino Acid Production in Cyanobacterial Bloom Cult… (Toxins 2024) · cited 5x in the literature
"Lake Winnipeg in Manitoba, Canada is heavily impacted by harmful algal blooms that contain non-protein amino acids (NPAAs) produced by cyanobacteria: N -(2-aminoethyl)glycine (AEG), β-aminomethyl-L-alanine (BAMA), β- N -methylamino-L-alanine (BMAA), and 2,4-diaminobutyric acid (DAB)." (abstract, background, passage verified)
pubmedfull study (doi)
Familial Alzheimer's disease accounts for less than 5% of Alzheimer's cases, and APP mutations represent less than 1% of Alzheimer's disease cases in humans.
"There are different ones now, there are the 5XFAD mice, which is basically they're saying FAD, familial Alzheimer's disease. Well, that's less than 5%. The mice that we worked with were typically APP mutants. APP mutations in humans represent less than 1% of Alzheimer's disease." (said at 0:51:09)
Autosomal dominant familial Alzheimer's disease (FAD) accounts for less than 1% to 5% of all Alzheimer's disease cases. Furthermore, pathogenic mutations in the amyloid precursor protein (APP) gene are even rarer, found in a minor fraction of early-onset cases (typically less than 0.5% to 1% of all Alzheimer's disease patients).
- supports: The genetics of Alzheimer's disease. (Scientifica 2012) · cited 102x in the literature
"Early onset Alzheimer's is rare, accounting for less than 5% of disease burden. It is inherited in Mendelian dominant fashion and is caused by mutations in three genes (APP, PSEN1, and PSEN2)." (abstract, passage verified)
pubmedfull study (doi) - supports: Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset… (Journal of neurology 2014) · cited 17x in the literature
"PSEN1 and APP mutations were found in, respectively 3.5 and 0.4 % of AD patients, and none in FTD patients." (abstract, passage verified)
pubmedfull study (doi) - supports: Early-Onset Alzheimer's Disease: What Is Missing in Research? (Current neurology and neuroscience reports 2021) · cited 198x in the literature
"EOAD cases make up 5-10% of AD cases but only 10-15% of these cases show known mutations in the APP, PSEN1, and PSEN2, which are linked to EOAD." (abstract, passage verified)
pubmedfull study (doi)
Sudden withdrawal of cholinesterase inhibitors can cause cognitive worsening due to compensatory upregulation of cholinesterase by the body.
"And the key thing is the people who suddenly cold turkey it could potentially get worse with their cognition because, as you know, your body now responds by making more cholinesterase, exactly what you don't want it to do. And so, if you suddenly cold turkey, you could be in a worse position than when you started." (said at 0:57:25)
Randomized trials and systematic reviews demonstrate that discontinuing cholinesterase inhibitors in patients with Alzheimer's disease is associated with significant cognitive and neuropsychiatric worsening compared to continuing treatment. A Cochrane systematic review of randomized trials found that discontinuation was associated with worse cognitive outcomes in both short-term and 12-month follow-ups. A meta-analysis of five randomized controlled trials similarly showed a statistically significant worsening in cognitive scores (Mini-Mental State Examination) and neuropsychiatric symptoms following discontinuation, leading clinical guidelines to recommend cautious tapering and monitoring when deprescribing.
- supports: Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-anal… (The Journal of clinical psychiatry 2015) · cited 64x in the literature
"Discontinued patients demonstrated a significant worsening of cognition (standard mean Mini-Mental State Examination difference: -0.29 [95% CI, -0.45 to -0.13], N = 300 continued/307 discontinued, P < .001), a significant worsening of neuropsychiatric symptoms (standard mean Neuropsychiatric Inventory difference: -0.32 [-0.51 to -0.12], N = 199/211, P = .001), and significantly higher dropout rates (risk ratio [RR] = 1.33 [1.11-1.59], N = 321/332, P = .002) compared to those who continued." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people wi… (The Cochrane database of systematic reviews 2021) · cited 43x in the literature
"Compared to continuing cholinesterase inhibitors, discontinuing treatment may be associated with worse cognitive function in the short term (standardised mean difference (SMD) -0.42, 95% confidence interval (CI) -0.64 to -0.21; 4 studies; low certainty), but the effect in the medium term is very uncertain (SMD -0.40, 95% CI -0.87 to 0.07; 3 studies; very low certainty). In a sensitivity analysis omitting data from a study which only included participants who had shown a relatively poor prior response to donepezil, inconsistency was reduced and we found that cognitive function may be worse in the discontinuation group in the medium term (SMD -0.62; 95% CI -0.94 to -0.31). Data from one longer-term study suggest that discontinuing a cholinesterase inhibitor is probably associated with worse cognitive function at 12 months (mean difference (MD) -2.09 Standardised Mini-Mental State Examination (SMMSE) points, 95% CI -3.43 to -0.75; moderate certainty)." (abstract, results, passage verified)
pubmedfull study (doi)
In Parkinson's disease, alpha-synuclein pathology can propagate physically from the gut to the brain via the vagus nerve.
"You know, there's so much in the literature these days that it's making it clear even from the physicality of the connection of the vagus nerve as it relates to alpha-synuclein making its way from the gut to the brain in the Parkinson's patients." (said at 0:59:54)
A substantial body of literature, originating with the Braak staging hypothesis, demonstrates that pathological alpha-synuclein aggregates can spread transneuronally from the enteric nervous system to the brain via the vagus nerve in models of Parkinson's disease. Landmark preclinical studies have shown that injecting preformed alpha-synuclein fibrils into the gastrointestinal muscularis leads to sequential spread via the vagus nerve to the dorsal motor nucleus in the brainstem and onward to the substantia nigra, causing dopaminergic loss and motor symptoms. Furthermore, surgical severance of the vagus nerve (truncal vagotomy) completely blocks this retrograde gut-to-brain spread and subsequent neurodegeneration.
The dithiocarbamate pesticides maneb and mancozeb are used in laboratory research to model Parkinson's disease by damaging cellular and mitochondrial function.
"You know, I was very taken a couple of years ago to learn that there's this chemical maneb and mancozeb that are used to create Parkinson's in the laboratory animal to damage cellular function, to damage the mitochondrial function in certain human-derived cells." (said at 1:00:35)
Maneb and mancozeb are manganese- and zinc-containing dithiocarbamate fungicides widely used in experimental laboratory models of Parkinson's disease. Animal studies in rodents and in vitro studies using isolated brain mitochondria, human neuroblastoma lines, and human-derived induced pluripotent stem cells (iPSCs) demonstrate that these compounds induce dopaminergic neurodegeneration by impairing cellular respiration, inhibiting electron transport chain complex III, decreasing ATP production, and disrupting mitochondrial function.
- supports: Acute neurotoxic effects of mancozeb and maneb in mesencephalic neuronal cultures are asso… (Neurotoxicology 2006) · cited 131x in the literature
"In whole mitochondrial preparations isolated from adult rat brains, MZ and MB inhibited NADH-linked state 3 respiration. Mild to moderate mitochondrial uncoupling was also observed in response to the fungicides. In conclusion, our findings indicate that acute exposure to high doses of MZ and MB produce equipotent toxic effects in both DA and GABA neurons that may be associated with perturbations in mitochondrial respiration." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2… (Cell 2013) · cited 441x in the literature
"Here, using a robust, patient-derived stem cell model of PD allowing comparison of A53T α-synuclein (α-syn) mutant cells and isogenic mutation-corrected controls, we identify mitochondrial toxin-induced perturbations in A53T α-syn A9 DA neurons (hNs)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Acute Maneb Exposure Significantly Alters Both Glycolysis and Mitochondrial Function in Ne… (Toxicological sciences : an official journal of the Society of Toxicology 2018) · cited 34x in the literature
"The pesticides paraquat (PQ) and maneb (MB) have been described as environmental risk factors for Parkinson's disease (PD), with mechanisms associated with mitochondrial dysfunction and reactive oxygen species generation. A combined exposure of PQ and MB in murine models and neuroblastoma cells has been utilized to further advance understanding of the PD phenotype." (abstract, results, passage verified)
pubmedfull study (doi)
COVID-19 infection is associated with viral brain entry, blood-brain barrier disruption, increased inflammatory cytokines (including IL-1 beta, IL-6, IL-10, and TNF-alpha), NMDA receptor stimulation, and kynurenine pathway activation producing quinolinic acid.
"We now know that there is actual evidence of entry of COVID into various parts of the brain. And some of these mechanisms include excitotoxicity, NMDA stimulation, kynurenic acid pathway with quinolinic acid being produced, increased inflammation as evidenced by increased levels of, you know, interleukin-1 beta, IL-6, IL-10, TNF-alpha, the vascular issues, the blood-brain barrier disruption, et cetera." (said at 0:35:20)
Published literature confirms that COVID-19 infection is associated with blood-brain barrier disruption, neuroinflammation driven by inflammatory cytokines, and activation of the kynurenine pathway leading to elevated levels of neurotoxic quinolinic acid (an NMDA receptor agonist implicated in excitotoxicity). Clinical and biomarker studies measuring cerebrospinal fluid (CSF) and plasma in acute and post-acute COVID-19 patients demonstrate significant upregulation of indoleamine 2,3-dioxygenase (IDO), increased tryptophan breakdown, and marked elevations of quinolinic acid and other kynurenine metabolites correlating with markers of neurodegeneration and neurological symptoms.
- supports: COVID-19, Oxidative Stress, and Neuroinflammation in the Depression Route. (Journal of molecular neuroscience : MN 2022) · cited 56x in the literature
"Inflammatory cytokines in the COVID-19 hyper inflammation process can activate the hypothalamic-pituitary-adrenal (HPA) axis and the indoleamine-2,3-dioxygenase (IDO) enzyme. IDO activation can reduce tryptophan and increase toxic metabolites of the kynurenine pathway, which increases glial activation, neuroinflammation, toxicity, and neuronal death." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Central and peripheral kynurenine pathway metabolites in COVID-19: Implications for neurol… (Brain, behavior, and immunity 2025) · cited 23x in the literature
"The present study reveals that the neuroactive kynurenine pathway metabolites quinolinic acid (QUIN) and kynurenic acid (KYNA) are increased in CSF in patients with acute COVID-19. In addition, CSF levels of kynurenine, ratio of kynurenine/tryptophan (rKT) and QUIN correlate with neurodegenerative markers." (abstract, results, passage verified)
pubmedfull study (doi)
In a clinical trial testing a multi-modal protocol for cognitive decline conducted by Dale Bredesen, Kat Toups, Ann Hathaway, and Deborah Gordon, the vast majority of participants showed clinical improvement.
"And in the trial, it was interesting. Not only did we see the vast majority of people get better, but interestingly, the few who did not get better, you could see why they weren't getting better... I do want to just quickly say that the people I work with on the trial, Dr. Kat Toups, who you know, Dr. Ann Hathaway, and Dr. Deborah Gordon, just absolutely fantastic functional medicine physicians and just did a great job." (said at 0:44:25)
A proof-of-concept pilot trial led by Kat Toups, Ann Hathaway, Deborah Gordon, Dale Bredesen, and colleagues evaluated a personalized multi-modal protocol in 25 participants with mild cognitive impairment or early dementia over 9 months. The published results reported statistically significant improvements in cognitive measures (including the Montreal Cognitive Assessment, CNS Vital Signs Neurocognitive Index, and Alzheimer's Questionnaire Change score) across the study group. Because the study was a small (n=25), uncontrolled pilot project without a randomized control arm, the certainty of the evidence for the protocol's general clinical efficacy is very low.
- supports: Precision Medicine Approach to Alzheimer's Disease: Successful Pilot Project. (Journal of Alzheimer's disease : JAD 2022) · cited 70x in the literature
"Twenty-five patients with dementia or mild cognitive impairment, with Montreal Cognitive Assessment (MoCA) scores of 19 or higher, were evaluated for markers of inflammation, chronic infection, dysbiosis, insulin resistance, protein glycation, vascular disease, nocturnal hypoxemia, hormone insufficiency or dysregulation, nutrient deficiency, toxin or toxicant exposure, and other biochemical parameters associated with cognitive decline... All outcome measures revealed improvement: statistically significant improvement in MoCA scores, CNS Vital Signs Neurocognitive Index, and Alzheimer's Questionnaire Change score were documented." (abstract, results, passage verified)
pubmedfull study (doi)
Exposure to toxins like trichloroethylene and annonacin increases the risk of Parkinson's disease.
"Absolutely huge increases, probably toxin-related, you know, trichloroethylene, things like that. Annonacin is another exposure that some people have that increases Parkinson's." (said at 1:02:27)
The claim that exposure to toxins like trichloroethylene (TCE) and annonacin increases the risk of Parkinson's disease (or parkinsonism) is supported by epidemiological studies and experimental rodent models.
A population-based cohort study of US veterans who served at Camp Lejeune found that exposure to drinking water contaminated with trichloroethylene (TCE) and other volatile organic compounds was associated with a 70% increased risk of Parkinson's disease (odds ratio 1.70, 95% CI 1.39-2.07) compared to unexposed controls (PMID: 37184848). Reviews and smaller epidemiological studies also report marked increases in Parkinson's disease risk linked to occupational and ambient TCE exposure (PMID: 36938742).
Regarding annonacin (a mitochondrial complex I inhibitor found in plants of the Annonaceae family such as soursop), epidemiological research in Guadeloupe linked its consumption to atypical parkinsonism. Experimental studies in rats demonstrate that systemic annonacin administration causes loss of dopaminergic neurons in the substantia nigra and mimics pathological features of parkinsonism (PMID: 14675150, PMID: 14521988).
While human evidence for annonacin relies primarily on observational data and animal models of atypical parkinsonism, the body of evidence for TCE includes large human cohort data, justifying a moderate certainty grade overall.
- supports: Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal … (Journal of neurochemistry 2004) · cited 252x in the literature
"In Guadeloupe, epidemiological data have linked atypical parkinsonism with fruit and herbal teas from plants of the Annonaceae family, particularly Annona muricata... Stereological cell counts showed significant loss of dopaminergic neurones in the substantia nigra (-31.7%)... These data are compatible with the theory that annonaceous acetogenins, such as annonacin, might be implicated in the aetiology of Guadeloupean parkinsonism" (abstract)
pubmedfull study (doi) - supports: Trichloroethylene: An Invisible Cause of Parkinson's Disease? (Journal of Parkinson's disease 2023) · cited 77x in the literature
"In addition, a small epidemiological study found that occupational or hobby exposure to the solvent was associated with a 500% increased risk of developing PD." (abstract, passage verified)
pubmedfull study (doi) - supports: Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune. (JAMA neurology 2023) · cited 86x in the literature
"In multivariable models, Camp Lejeune veterans had a 70% higher risk of PD (odds ratio, 1.70; 95% CI, 1.39-2.07; P < .001)... The study's findings suggest that the risk of PD is higher in persons exposed to TCE and other VOCs in water 4 decades ago." (abstract, results and conclusions)
pubmedfull study (doi)
Whole coffee fruit extract increases brain-derived neurotrophic factor (BDNF).
"Simple things like whole coffee fruit extract, which you actually taught me about a few years ago. So, thank you for that. Very interesting, and increases BDNF and has turned out to be a very interesting supplement" (said at 1:04:26)
Clinical trial evidence demonstrates that whole coffee fruit concentrate/extract acutely increases circulating levels of brain-derived neurotrophic factor (BDNF). In a randomized human study, a single 100 mg dose of whole coffee fruit concentrate powder produced a 143% increase in plasma BDNF levels over baseline compared to control treatments, though the sample size in the initial trial was small.
A lifestyle intervention program published by Kara Fitzgerald showed a 3.5-year reversal of the Horvath DNA methylation clock.
"Kara Fitzgerald, who recently published a wonderful paper about a 3 and 1/2 year reversal of the Horvath DNA methylation clock via an interventional lifestyle program, which was a specific program, but not uniquely personalized." (said at 1:07:05)
Kara Fitzgerald and colleagues published a pilot randomized clinical trial in 43 healthy men aged 50–72 evaluating an 8-week multimodal diet and lifestyle intervention. Compared with the control group, the intervention group demonstrated a 3.23-year reduction in biological age as measured by the Horvath DNAmAge clock (p = 0.018). Within the intervention group, the average decrease from baseline was 1.96 years (p = 0.066). While the published study matches the speaker's description, certainty is low due to the small sample size and pilot nature of the trial.
- supports: Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot rand… (Aging 2021) · cited 371x in the literature
"The diet and lifestyle treatment was associated with a 3.23 years decrease in DNAmAge compared with controls (p=0.018). DNAmAge of those in the treatment group decreased by an average 1.96 years by the end of the program compared to the same individuals at the beginning with a strong trend towards significance (p=0.066). To our knowledge, this is the first randomized controlled study to suggest that specific diet and lifestyle interventions may reverse Horvath DNAmAge (2013) epigenetic aging in healthy adult males." (abstract, results, passage verified)
pubmedfull study (doi)
Fructose metabolizes into uric acid, and uric acid plays a pivotal role in insulin resistance, inflammation, and non-alcoholic fatty liver disease.
"keeping people off of fructose or recommending that in what I write, because of their ultimate metabolism down to uric acid, because we're learning so much now about the pivotal role of uric acid sort of as an orchestrator of insulin resistance, inflammation, non-alcoholic fatty liver disease, etc." (said at 1:08:24)
Fructose metabolism in the liver via fructokinase (ketohexokinase) causes rapid ATP depletion, nucleotide turnover, and purine degradation, resulting in the generation of uric acid. Experimental and clinical evidence demonstrates that hyperuricemia and intracellular uric acid accumulation contribute to mitochondrial oxidative stress, low-grade inflammation, de novo lipogenesis, and impaired insulin signaling, promoting insulin resistance and non-alcoholic fatty liver disease (NAFLD/MASLD).
- supports: Uric Acid as a Cause of the Metabolic Syndrome. (Contributions to nephrology 2018) · cited 199x in the literature
"Experimental studies have also shown that hyperuricemia may mediate insulin resistance, fatty liver, and dyslipidemia in both fructose-dependent and fructose-independent models of metabolic syndrome. The mechanism for uric acid-induced insulin resistance appears to be mediated by the development of mitochondrial oxidative stress and impairment of insulin-dependent stimulation of nitric oxide in endothelial cells." (abstract, passage verified)
pubmedfull study (doi) - supports: Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. (Journal of hepatology 2018) · cited 942x in the literature
"Recent evidence suggests that the predisposition to fatty liver is linked to the metabolism of fructose by fructokinase C, which results in ATP consumption, nucleotide turnover and uric acid generation that mediate fat accumulation." (abstract, passage verified)
pubmedfull study (doi) - supports: The Impact of Fructose Consumption on Human Health: Effects on Obesity, Hyperglycemia, Dia… (Cureus 2024) · cited 18x in the literature
"Furthermore, fructose-induced adenosine triphosphate depletion activates purine degradation, increasing uric acid levels and exacerbating hyperuricemia. The overproduction of reactive oxygen species during fructose metabolism also drives oxidative stress, promoting inflammation and cellular damage." (abstract, passage verified)
pubmedfull study (doi)
Gluten consumption has an impact on intestinal permeability (leaky gut).
"And especially focusing on gluten. It's a huge issue because of its impact, especially on leaky gut." (said at 1:02:40)
Evidence from ex vivo human intestinal biopsy explants, animal models, and cell line studies demonstrates that exposure to gliadin (a major component of gluten) triggers zonulin release, tight junction disassembly, and increases intestinal permeability. While this effect occurs to some degree in non-celiac controls, it is more pronounced and sustained in individuals with active celiac disease and non-celiac gluten sensitivity.
Organ meats, sardines, and scallops are high sources of purines that metabolize into uric acid.
"certainly organ meats and higher sources of purines like sardines and scallops... because of their ultimate metabolism down to uric acid" (said at 1:08:24)
Dietary purines from meats and seafood (including organ meats, sardines, and shellfish) are well-established substrates that are metabolized into uric acid in humans. Large epidemiological analyses, such as data from NHANES III (PMID: 15641075), demonstrate that higher intake of meat and seafood is significantly associated with elevated serum uric acid levels.
- supports: Intake of purine-rich foods, protein, and dairy products and relationship to serum levels … (Arthritis and rheumatism 2005) · cited 605x in the literature
"These findings from a nationally representative sample of adults in the US suggest that higher levels of meat and seafood consumption are associated with higher serum levels of uric acid but that total protein intake is not." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: A prescription for lifestyle change in patients with hyperuricemia and gout. (Current opinion in rheumatology 2010) · cited 233x in the literature
"Large-scale studies have clarified a number of long-suspected relations between lifestyle factors, hyperuricemia, and gout, including purine-rich foods, dairy foods, various beverages, fructose, and vitamin C supplementation." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.